Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study

INTRODUCTION: Somatrogon is a long-acting recombinant human growth hormone being developed as a once-weekly treatment for children with growth hormone deficiency (GHD). The objective of this phase 3 study (NCT03874013) was to compare the efficacy and safety of once-weekly somatrogon with once-daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Horikawa, Reiko, Tanaka, Toshiaki, Hasegawa, Yukihiro, Yorifuji, Tohru, Ng, David, Rosenfeld, Ron G., Hoshino, Yuko, Okayama, Akifumi, Shima, Daisuke, Gomez, Roy, Pastrak, Aleksandra, Castellanos, Orlando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533447/
https://www.ncbi.nlm.nih.gov/pubmed/35417909
http://dx.doi.org/10.1159/000524600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533447/
https://www.ncbi.nlm.nih.gov/pubmed/35417909
http://dx.doi.org/10.1159/000524600

Ejemplares similares